Metrics as of 10/15/2026, 01:08 PM (Berlin time), refresh in progress.
BioStem Technologies Stock
BioStem Technologies, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jason Matuszewski
- Employees
- 73
- Market cap
- $39 M
- IPO
- 17/03/2015
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a…
BioStem Technologies stock: price history
1D
-6.2%
1W
-11.7%
1M
-49.9%
6M
-54.9%
YTD
-44.6%
1Y
-55.1%
2Y
-82.4%
5Y
+50.7%
10Y
-78.7%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~16% stronger price swings than usual
Ask the agents about BioStem Technologies
Analyst assessment of BioStem Technologies
PRICE TARGET LOW
US$7.00
CONSENSUS
US$7.00
MEDIAN
US$7.00
PRICE TARGET HIGH
US$7.00
No current analyst ratings available.
BioStem Technologies stock metrics
P/E
-1.27
P/B
1.32
EV/EBITDA
-1.54
RETURN ON EQUITY
-32.5%
NET MARGIN
-113.6%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
71.0%
FLOAT SHARES
13,257,901
AVG. DAILY VOLUME (30D)
162,706
Insider transactions (SEC)
Matuszewski Jason
SMITH-VAN VURST ANDREW
FORTUNATO MICHAEL A
WARRINGTON KENNETH HOWARD JR
SMITH-VAN VURST ANDREW
Dividends & Stock splits
Comparable stocks
Frequently asked questions about BioStem Technologies stock
What does BioStem Technologies do?
BioStem Technologies, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jason Matuszewski, the company employs around 73 people.
The IPO was on 17/03/2015; the stock trades on NASDAQ under the ticker BSEM.
What do analysts say about BioStem Technologies stock?
The average price target is US$7.00, ranging from US$7.00 to US$7.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
When does BioStem Technologies report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 16% stronger than usual.
Does BioStem Technologies pay a dividend?
No, BioStem Technologies currently does not pay a dividend.
Which stocks are comparable to BioStem Technologies?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get BioStem Technologies stock analyzed?
Clicking "Analyze stock" lets five strategies assess BioStem Technologies against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.